SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

CalciMedica, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

Evgeny Zaytsev
601 California Street, Suite 620,
San Francisco, CA, 94108
(415) 484-1221

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/19/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Bering Partners II GP, L.L.C.
2	Check the appropriate box if a member of a Group (See Instructions)

☐ (a)
☑ (b)

3	SEC use only	
4	Source of funds (See Instructions) AF	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 3,553,398.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 3,553,398.00
11	Aggregate amount beneficially owned by each reporting person 3,553,398.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 9.99 %	
14	Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: Consists of (i) 2,113,513 shares of Common Stock (as defined in Item 1(a)), (ii) 130,651 shares of Common Stock underlying Common Stock Warrants (the Common Stock Warrants) which are exercisable within 60 days of this Statement, (iii) 654,617 shares of Common Stock underlying certain Series A Warrants (as defined in Item 3(a)) which are exercisable within 60 days of this Statement, and (iv) 654,617 shares of Common Stock underlying certain Series B Warrants (as defined in Item 3(a)) which are exercisable within 60 days of this Statement. This total excludes (a) 795,650 shares of Common Stock issuable upon exercise of certain Series A Warrants and (b) 795,650 shares of Common Stock issuable upon exercise of certain Series B Warrants because the Series A Warrants and Series B Warrants contain a provision which prohibits the exercise of the Series A Warrants and Series B Warrants to the extent that doing so would result in the holder of the Series A Warrants and Series B Warrants (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates) beneficially owning more than 9.99 percent of the shares of Common Stock then outstanding immediately after giving effect to such exercise (the Beneficial Ownership Limitation). All securities are held by Bering II (as defined in Item 2(a)). Bering II GP (as defined in Item 2(a)) is the general partner of Bering II and may be deemed to have voting and dispositive power over the shares held by Bering II. Mr. Zaytsev (as defined in Item 2(a)), a member of the Issuer's board of directors (the Board), and Mr. Sawyer (as defined in Item 2(a)) are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Based on 35,581,345 shares, as follows: (i) 34,141,460 of Common Stock outstanding as of August 5, 2026, as reported by the Issuer (as defined in Item 1(b)) in its Form 10-Q filed with the United States Securities and Exchange Commission (the Commission) on August 11, 2026 (the Form 10-Q), plus (ii) an aggregate of 1,439,885 shares of Common Stock underlying Common Stock Warrants, Series A Warrants and Series B Warrants (together, the Warrants) which are exercisable within 60 days of this Statement.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Bering Partners II, L.P.		
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)		
3	SEC use only		
4	Source of funds (See Instructions) WC		
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐		
6	Citizenship or place of organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00	
	8	Shared Voting Power 3,553,398.00	
	9	Sole Dispositive Power 0.00	
	10	Shared Dispositive Power 3,553,398.00	
11	Aggregate amount beneficially owned by each reporting person 3,553,398.00		
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐		
13	Percent of class represented by amount in Row (11) 9.99 %		
14	Type of Reporting Person (See Instructions) PN		

Comment for Type of Reporting Person: Consists of (i) 2,113,513 shares of Common Stock, (ii) 130,651 shares of Common Stock underlying Common Stock Warrants which are exercisable within 60 days of this Statement, (iii) 654,617 shares of Common Stock underlying certain Series A Warrants which are exercisable within 60 days of this Statement, and (iv) 654,617 shares of Common Stock underlying certain Series B Warrants which are exercisable within 60 days of this Statement. This total excludes (a) 795,650 shares of Common Stock issuable upon exercise of certain Series A Warrants and (b) 795,650 shares of Common Stock issuable upon exercise of certain Series B Warrants due to the Beneficial Ownership Limitation. All securities are held by Bering II. Bering II GP is the general partner of Bering II and may be deemed to have voting and dispositive power over the shares held by Bering II. Mr. Zaytsev, a member of the Issuer's Board, and Mr. Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Based on 35,581,345 shares, as follows: (i) 34,141,460 of Common Stock outstanding as of August 5, 2026, as reported by the Issuer in the Form 10-Q, plus (ii) an aggregate of 1,439,885 shares of Common Stock issuable upon exercise of the Warrants which are exercisable within 60 days of this Statement.

1	Name of reporting person Evgeny Zaytsev
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:		
	7	Sole Voting Power 0.00
	8	Shared Voting Power 3,553,398.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 3,553,398.00

11	Aggregate amount beneficially owned by each reporting person 3,553,398.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13	Percent of class represented by amount in Row (11) 9.99 %
14	Type of Reporting Person (See Instructions) IN

Comment for Type of Reporting Person: Consists of (i) 2,113,513 shares of Common Stock, (ii) 130,651 shares of Common Stock underlying Common Stock Warrants which are exercisable within 60 days of this Statement, (iii) 654,617 shares of Common Stock underlying certain Series A Warrants which are exercisable within 60 days of this Statement, and (iv) 654,617 shares of Common Stock underlying certain Series B Warrants which are exercisable within 60 days of this Statement. This total excludes (a) 795,650 shares of Common Stock issuable upon exercise of certain Series A Warrants and (b) 795,650 shares of Common Stock issuable upon exercise of certain Series B Warrants due to the Beneficial Ownership Limitation. All securities are held by Bering II. Bering II GP is the general partner of Bering II and may be deemed to have voting and dispositive power over the shares held by Bering II. Mr. Zaytsev, a member of the Issuer's Board, and Mr. Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Based on 35,581,345 shares, as follows: (i) 34,141,460 of Common Stock outstanding as of August 5, 2026, as reported by the Issuer in the Form 10-Q, plus (ii) an aggregate of 1,439,885 shares of Common Stock issuable upon exercise of the Warrants which are exercisable within 60 days of this Statement.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person

1	Names of Reporting Persons Philip M Sawyer
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 3,553,398.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 3,553,398.00

11	Aggregate amount beneficially owned by each reporting person 3,553,398.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13	Percent of class represented by amount in Row (11) 9.99 %
14	Type of Reporting Person (See Instructions) IN

Comment for Type of Reporting Person: Consists of (i) 2,113,513 shares of Common Stock, (ii) 130,651 shares of Common Stock underlying Common Stock Warrants which are exercisable within 60 days of this Statement, (iii) 654,617 shares of Common Stock underlying certain Series A Warrants which are exercisable within 60 days of this Statement, and (iv) 654,617 shares of Common Stock underlying certain Series B Warrants which are exercisable within 60 days of this Statement. This total excludes (a) 795,650 shares of Common Stock issuable upon exercise of certain Series A Warrants and (b) 795,650 shares of Common Stock issuable upon exercise of certain Series B Warrants due to the Beneficial Ownership Limitation. All securities are held by Bering II. Bering II GP is the general partner of Bering II and may be deemed to have voting and dispositive power over the shares held by Bering II. Mr. Zaytsev, a member of the Issuer's Board, and Mr. Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Based on 35,581,345 shares, as follows: (i) 34,141,460 of Common Stock outstanding as of August 5, 2026, as reported by the Issuer in the Form 10-Q, plus (ii) an aggregate of 1,439,885 shares of Common Stock issuable upon exercise of the Warrants which are exercisable within 60 days of this Statement.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: CalciMedica, Inc.

(c) Address of Issuer's Principal Executive Offices:

505 Coast Boulevard South, Suite 307, La Jolla, CALIFORNIA , 92037.

Item 1 Comment: Explanatory Note: This Amendment No. 1 amends and supplements the Schedule 13D originally filed with the Commission on July 2, 2026 (the Original Schedule 13D) and is being filed by Bering Partners II, L.P. ("Bering II") and Bering Partners II GP, L.L.C. ("Bering II GP", and together with Bering II, the Reporting Entities), Mr. Evgeny Zaytsev ("Mr. Zaytsev") and Mr. Philip Sawyer ("Mr. Sawyer"). The Reporting Entities, Mr. Zaytsev, a member of the Issuer's Board, and Mr. Sawyer are collectively referred to as the Reporting Persons. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to the Original Schedule 13D as Exhibit 1. Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 1 have the meanings ascribed to them in the Original Schedule 13D.

Item 2. Identity and Background

(a) The information set forth in Item 2(a) of the Original Schedule 13D is incorporated herein by reference.

(b) The information set forth in Item 2(b) of the Original Schedule 13D is incorporated herein by reference.

(c) The information set forth in Item 2(c) of the Original Schedule 13D is incorporated herein by reference.

(d) The information set forth in Item 2(d) of the Original Schedule 13D is incorporated herein by reference.

(e) The information set forth in Item 2(e) of the Original Schedule 13D is incorporated herein by reference.

(f) The information set forth in Item 2(f) of the Original Schedule 13D is incorporated herein by reference.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Original Schedule 13D is hereby amended by the addition of the following information: The Stockholder Approval for the issuance of the Series A Warrants and Series B Warrants was obtained on August 19, 2026, and the Series A Warrants and Series B Warrants held by Bering II were issued on the same day.

Item 4. Purpose of Transaction

The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference.

Item 5. Interest in Securities of the Issuer

(a) See Items 7-11 of the cover pages of this Statement and Item 2 above. Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

(b) See Items 7-11 of the cover pages of this Statement and Item 2 above. Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

(c) Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days.

(d) The information set forth in Item 5(d) of the Original Schedule 13D is incorporated herein by reference.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

The information set forth in Item 6 of the Original Schedule 13D is incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bering Partners II GP, L.L.C.

Signature: /s/ Evgeny Zaytsev
Name/Title: Evgeny Zaytsev, Managing Member
Date: 08/21/2026

Bering Partners II, L.P.

Signature: /s/ Evgeny Zaytsev
Name/Title: Evgeny Zaytsev, Managing Member of the General Partner
Date: 08/21/2026

Evgeny Zaytsev

Signature: /s/ Evgeny Zaytsev
Name/Title: Evgeny Zaytsev

Date: 08/21/2026

Philip M Sawyer

Signature: /s/ Philip Sawyer
Name/Title: Philip Sawyer
Date: 08/21/2026